Takeda secures conditional approval in the UK for Exkivity

The British business of Japanese pharma major Takeda Pharmaceutical (TYO: 4502) has secured conditional approval in the UK for its first-in-class oral tyrosine kinase inhibitor (TKI) Exkivity (mobocertinib).

The nod comes around six months after the US Food and Drug Administration granted an Accelerated Approval for the therapy in non-small cell lung cancer (NSCLC).

Exkivity is part of what Takeda regards as a “first wave” of around a dozen emerging drugs which represent the output from major investments in R&D and acquisitions.